ClinicalTrials.gg
Drug

Cefepime clinical trials

Also written Maxipime.

studies test it
22
open now
2
in phase 3
6
first study started
2001

Counted the way a researcher would: Cefepime with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Cefepime is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Cefepime studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Jan 1996 · MAXIPIME · NDA 050679 (FDA, Drugs@FDA)
European Union
21 Mar 2024 · Exblifep · EMEA/H/C/005431 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cefepime
12
Cefepime Injection
2
cefepime hydrochloride
2
Cefepime 2000 mg
2

Brand

Maxipime
4

Studies by the year they started

22 studies that test it; most in 2019 (3)

Studies that test Cefepime, by start year
YearStudies
20011
20021
20061
20102
20111
20131
20152
20162
20172
20193
20213
20232
20261

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
4
Phase 3
6
Phase 4
8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 15

Allecra (2) · Wockhardt (2) · Janssen Research & Development, LLC (2) · Memorial Sloan Kettering Cancer Center (1) · Beni-Suef University (1) · Murdoch Childrens Research Institute (1) · Centre Hospitalier Universitaire de Besancon (1) · Indonesia University (1)

Often tested with

Tested in the same studies.

Piperacillin, Tazobactam Drug Combination (4) · Vancomycin (3) · Meropenem (3) · Piperacillin (2) · Tazobactam (2) · Enmetazobactam (2) · Ceftriaxone (2) · Levofloxacin (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Cefepime.

Studies

Open first, then newest update. How each study uses Cefepime is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 22

See all 22 studies that test Cefepime →

Given beside what is tested · 9 — Cefepime is usual care or a partner of the new treatment
As the comparator · 9 — what is tested is compared with Cefepime

Codes

What other systems call Cefepime · ClinicalTrials.gg INT006791

  • MeSH (NLM) D000077723CefepimeConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 807PW4VQE3CEFEPIMEConfirmed FDA, NLM, Wikidata
  • RxNorm 20481Confirmed FDA, Wikidata
  • Wikidata Q2552927cefepimeConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C65294CefepimeOne source FDA
  • DrugBank DB01413One source Wikidata

Also registered as cefepime hydrochloride (UNII I8X1O0607P · RxNorm 236058).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.